Table 10.
GO Biological processes with highest joint ranks for all viruses for the NHBE cell type. Counts correspond to the normalized number of occurrences of each process within each condition.
| GO Biological Processes | NHBE SARS-CoV-2 |
NHBE IAV |
NHBE IAVdNS1 |
||||||
|---|---|---|---|---|---|---|---|---|---|
| count | p-value | c-score | count | p-value | c-score | count | p-value | c-score | |
| extracellular matrix organization (GO:0030198) | 1.00 | 3.31E-08 | 1.70E+02 | 1.00 | 3.31E-08 | 1.70E+02 | 0.84 | 3.31E-08 | 1.70E+02 |
| cardiac muscle tissue development (GO:0048738) | 0.79 | 4.78E-03 | 3.00E+02 | 0.91 | 4.78E-03 | 3.00E+02 | 0.80 | 4.78E-03 | 3.00E+02 |
| inflammatory response (GO:0006954) | 0.75 | 3.90E-04 | 1.47E+02 | 0.91 | 3.90E-04 | 2.71E+02 | 1.00 | 3.90E-04 | 2.71E+02 |
| dendritic cell migration (GO:0036336) | 0.75 | 6.79E-03 | 5.92E+02 | 0.86 | 6.79E-03 | 5.92E+02 | 0.77 | 6.79E-03 | 5.92E+02 |
| dendritic cell chemotaxis (GO:0002407) | 0.75 | 6.71E-03 | 7.08E+02 | 0.86 | 6.71E-03 | 7.08E+02 | 0.77 | 6.71E-03 | 7.08E+02 |
| cellular response to interferon-gamma (GO:0071346) | 0.88 | 4.31E-03 | 3.97E+02 | 0.79 | 4.31E-03 | 5.12E+02 | 0.75 | 7.60E-04 | 1.13E+03 |
| extracellular structure organization (GO:0043062) | 0.75 | 1.10E-07 | 8.85E+01 | 0.86 | 1.10E-07 | 8.85E+01 | 0.70 | 1.10E-07 | 8.85E+01 |
| external encapsulating structure organization (GO:0045229) | 0.75 | 4.67E-08 | 9.64E+01 | 0.86 | 4.67E-08 | 9.64E+01 | 0.70 | 4.67E-08 | 9.64E+01 |
| regulation of immune response (GO:0050776) | 0.71 | 5.14E-03 | 1.85E+02 | 0.79 | 5.14E-03 | 1.85E+02 | 0.82 | 5.14E-03 | 1.85E+02 |
| negative regulation of T cell activation (GO:0050868) | 0.75 | 9.83E-03 | 1.13E+03 | 0.77 | 3.11E-03 | 4.28E+02 | 0.66 | 3.11E-03 | 4.28E+02 |
| phospholipase receptor signaling pathway (GO:0007200) | 0.67 | 9.33E-03 | 2.60E+02 | 0.81 | 9.33E-03 | 2.60E+02 | 0.66 | 9.33E-03 | 2.60E+02 |
| regulation of T cell proliferation (GO:0042129) | 0.67 | 7.93E-04 | 4.13E+02 | 0.77 | 7.93E-04 | 4.13E+02 | 0.66 | 7.93E-04 | 4.13E+02 |
| chemokine-mediated signaling pathway (GO:0070098) | 0.67 | 1.55E-04 | 5.04E+02 | 0.67 | 1.55E-04 | 5.04E+02 | 0.68 | 4.01E-04 | 5.04E+02 |
| positive regulation of chemotaxis (GO:0050921) | 0.62 | 6.71E-03 | 3.42E+02 | 0.79 | 6.71E-03 | 9.51E+02 | 0.59 | 6.71E-03 | 9.51E+02 |
| cellular response to cytokine stimulus (GO:0071345) | 0.92 | 2.50E-04 | 6.55E+05 | 0.70 | 2.90E-03 | 1.42E+02 | 0.52 | 2.90E-03 | 2.98E+02 |
| positive regulation of lymphocyte proliferation (GO:0050671) | 0.54 | 3.72E-03 | 1.66E+02 | 0.70 | 3.72E-03 | 1.66E+02 | 0.70 | 8.75E-03 | 3.05E+02 |
| complement activation, classical pathway (GO:0006958) | 0.58 | 4.54E-05 | 8.66E+03 | 0.70 | 4.54E-05 | 9.67E+03 | 0.61 | 4.54E-05 | 9.67E+03 |
| nervous system development (GO:0007399) | 0.54 | 3.84E-03 | 3.69E+01 | 0.74 | 3.84E-03 | 3.74E+01 | 0.61 | 3.84E-03 | 3.56E+01 |
| heart development (GO:0007507) | 0.54 | 2.69E-03 | 7.04E+01 | 0.74 | 2.69E-03 | 7.04E+01 | 0.61 | 2.69E-03 | 7.04E+01 |
| positive regulation of MAPK cascade (GO:0043410) | 0.54 | 9.24E-06 | 2.95E+02 | 0.70 | 9.24E-06 | 2.95E+02 | 0.66 | 9.24E-06 | 2.95E+02 |
| cellular response to chemokine (GO:1990869) | 0.62 | 1.94E-04 | 4.57E+02 | 0.63 | 1.94E-04 | 4.57E+02 | 0.75 | 4.14E-04 | 4.57E+02 |
| regulation of calcium ion-dependent exocytosis (GO:0017158) | 0.54 | 4.08E-03 | 1.91E+02 | 0.72 | 4.08E-03 | 1.91E+02 | 0.59 | 4.08E-03 | 1.91E+02 |
| positive regulation of ERK1 and ERK2 cascade (GO:0070374) | 0.54 | 6.12E-05 | 2.77E+02 | 0.70 | 6.12E-05 | 2.77E+02 | 0.61 | 6.12E-05 | 2.77E+02 |
| B cell receptor signaling pathway (GO:0050853) | 0.54 | 7.09E-04 | 5.07E+02 | 0.70 | 7.09E-04 | 5.07E+02 | 0.61 | 7.09E-04 | 5.07E+02 |
| calcium-mediated signaling (GO:0019722) | 0.54 | 6.85E-03 | 1.07E+02 | 0.70 | 6.85E-03 | 1.07E+02 | 0.61 | 6.85E-03 | 1.07E+02 |